undamentalytics Newsletter
Sign in

CG Oncology, Inc. balance sheet

At the end of fiscal 2025, CG Oncology, Inc. had total assets of $792m, total liabilities of $39.0m and shareholders' equity of $753m. It held $32.5m in cash against $3.0m of debt: net cash of $29.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents82573220
Receivables0010
Inventory—021
Total current assets1947547591,050
Goodwill—01010
Total assets1997557921,086
Accounts payable37613
Total current liabilities14213147
Long-term debt—033
Total debt0033
Total liabilities15213957
Shareholders' equity−1237337531,029
Non-controlling interests and other (assets − liabilities − equity)308———
Net debt (negative = net cash)−8−257−29−17
Shares outstanding—76m81m88m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CGON vs FATECGON vs HCWBCGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from CG Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to CG Oncology, Inc.